BofA upgraded Oscar Health to Buy from Neutral with a price target of $9, up from $8. The firm expects the insurer to report “strong” Q3 results and give “positive” 2024 guidance as the company is benefitting by raising prices above peers and from overall market growth due to Medicaid expansion, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>